Project Grant R01CA273001
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$403K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This $601,091 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to The Ohio State University will support research to identify a novel drug target, S100A9, to prevent paclitaxel-induced peripheral neuropathy (PIPN) in cancer patients without compromising the drug's antitumor efficacy. The research aims to: (I) characterize the mechanism by which S100A9 contributes to PIPN, focusing on neuro-immune interactions; (II) determine an optimal regimen to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $661,122 in funding to The Trustees of Columbia University in the City of New York to investigate the pathogenic role of tubulin post-translational modifications in chemotherapy-induced peripheral neuropathy (CIPN). The research aims to evaluate whether the accumulation of delta-2 tubulin, an irreversible tubulin modification, plays a common pathogenic role in the neuropathic...
This $419,474 project grant from the National Cancer Institute, part of the Department of Health and Human Services, supports research under the Cancer Treatment Research program to develop mechanism-based strategies to treat chemotherapy-induced peripheral neuropathy. The awardee, Washington University, will utilize a SARM1 dominant-negative construct and virus-mediated overexpression of NAD+ salvage pathway enzymes to block the axon degeneration pathway activated by chemotherapeutic agents...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $589,106 to The Washington University in St. Louis to investigate the role of senescent stromal cells in chemotherapy-induced peripheral neuropathy (CIPN). The research aims to 1) elucidate the impact of senescence on axonal loss in CIPN, and 2) identify senescent cells and determine how they contribute to CIPN. The award period runs from June 1, 2025 to March 31, 2030. The research...
The U.S. National Cancer Institute (NCI) awarded a $179,403 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Nebraska Medical Center (UNMC) to develop and screen novel flupirtine analogue compounds for the treatment of chemotherapy-induced neuropathic pain (CINP). The project aims to strategically modify the flupirtine molecular structure to enhance liver safety while maintaining or improving its analgesic efficacy against CINP. Specifically, the research involves (1)...
This $544,478 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to The University of Texas Southwestern Medical Center will support research to investigate the mechanisms and metabolic pathways that regulate purine nucleotide synthesis in cancer cells. The project aims to provide critical insights into how major oncogenic signaling pathways control the salvage and de novo purine synthesis pathways, how dietary nucleotides influence tumor cell...
This $255,769 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports the development of a novel proxy-report survey to screen for chemotherapy-induced peripheral neuropathy (CIPN) in young children aged 1-5 years. The grant recipient, Yale University, will 1) use qualitative research methods to develop survey items to screen for CIPN symptoms, 2) prospectively evaluate the survey's psychometric properties, and 3) collect preliminary...
This federal Project Grant award of $524,419 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of Toledo Health Science Campus to investigate the molecular basis of fatty acid synthase (FASN) regulation and its role in overcoming resistance to PARP inhibitors (PARPi) in triple-negative breast cancer (TNBC). The key objectives are to: 1) determine how proton pump inhibitors (PPIs) inhibit FASN function, 2) elucidate the mechanism by...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the role of tau phosphorylation in diabetic peripheral neuropathy. The award, totaling $207,960, will fund a research project at the University of Texas MD Anderson Cancer Center to identify increases in tau phosphorylation and insulin signaling dysregulation in the sciatic nerve of a diabetic neuropathy model....
This $355,843 federal Project Grant awarded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research by The Trustees of Columbia University in the City of New York to investigate the role of purinergic signaling in mediating the effects of neuronal activity, including seizures, on glioma progression. The project aims to utilize in vitro imaging, ex vivo electrophysiology, and in vivo two-photon and wide-field optical imaging to better understand how...